基于免疫细胞的 COVID-19 治疗：现状。
Immune-Cell-Based Therapy for COVID-19: Current Status.
机构信息
Laboratory of Anti-Inflammatory and Immunomodulatory Pharmacology, Innovation Program of Drug Research on Inflammatory and Immune Diseases, Southern Medical University, Guangzhou 510515, China.
NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
出版信息
Viruses. 2023 Oct 25;15(11):2148. doi: 10.3390/v15112148.
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy to modulate the immune system, offering immense potential for the treatment of COVID-19 due to its customizability and regenerative capabilities. This review provides an overview of the various subsets of immune cell subsets implicated in the pathogenesis of COVID-19 and a comprehensive summary of the current status of immune cell therapy in COVID-19 treatment.
新型冠状病毒病 2019（COVID-19），由严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起，已成为全球大流行疾病。先天免疫和适应性免疫反应的相互作用在管理 COVID-19 中起着至关重要的作用。细胞疗法最近作为一种调节免疫系统的有前途的策略出现，由于其可定制性和再生能力，为 COVID-19 的治疗提供了巨大的潜力。本综述概述了参与 COVID-19 发病机制的各种免疫细胞亚群，并全面总结了免疫细胞治疗在 COVID-19 治疗中的现状。
Zotero 插件